EMA Authorised: Desloratadine Actavis (desloratadine) — Actavis Group PTC ehf

View source ↗

Summary

The EMA has authorised Desloratadine Actavis (desloratadine) for allergic rhinitis and urticaria indications in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Perennial Allergic Rhinitis
• Seasonal Allergic Rhinitis
• Urticaria

Drugs mentioned

• Desloratadine Actavis (desloratadine)

Snippet

Status: Authorised. Therapeutic area: Rhinitis, Allergic, Perennial;Urticaria;Rhinitis, Allergic, Seasonal. MAH: Actavis Group PTC ehf. Decision date: 31/05/2023